sign in sign up
<<
Home , Fevipiprant, Laropiprant, Prostaglandin analogue, Prostaglandin D2, Prostaglandin receptor, Ramatroban

Prostaglandin

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

www.MedChemExpress.com 1 Inhibitors, Agonists, Antagonists, Activators & Modulators

(+)- (-)-Curine (D-Cloprostenol) Cat. No.: HY-107381 Cat. No.: HY-N2569

(+)-Cloprostenol is a prostaglandin F2α (PGF2α) (-)-Curine is an orally active analogue, and shows selective agonistic activity bisbenzylisoquinoline alkaloid isolated from at the prostaglandin receptor. Chondrodendron platyphyllum. (-)-Curine presents anti-inflammatory and analgesic effects at nontoxic doses, at least in part, resulting from the inhibition of production. Purity: 98.05% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg Size: 1 mg, 5 mg

16,16-Dimethyl prostaglandin E2 2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide (16,16-dimethyl PGE2) Cat. No.: HY-106420 Cat. No.: HY-100287

16,16-Dimethyl prostaglandin E2 (16,16-dimethyl 2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) PGE2) is an orally active vertebrate sulfide is a compound that inhibits stress-induced Hematopoietic stem cells (HSCs) homeostasis ulcer and low toxicity, and can maintain the critical regulator. 16,16-Dimethyl prostaglandin content of A2 and prostaglandin E2 E2 can act through EP2/EP4 and has an interaction in ulcerated rats induced by water immersed with the Wnt pathway. restrained stress. Purity: ≥98.0% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg Size: 1 mg, 5 mg

Aganepag AGN 210676 (AGN 210937) Cat. No.: HY-19864 (Simenepag) Cat. No.: HY-14898

Aganepag is a potent EP2 receptor AGN 210676 is a selective prostaglandin EP2

agonist, with an EC50 of 0.19 nM, and shows no agonist extracted from patent US20070203222A1,

activity at EP4 receptor. Aganepag can be used in Compound example 23, has an EC50 of 5 nM. the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Agnuside AH 6809 (Agnoside) Cat. No.: HY-N2518 Cat. No.: HY-10418

Agnuside is a compound isolated from Vitex negundo, AH 6809 is an antagonist of EP and DP receptor,

down-regulates pro-inflammatory mediators PGE2 with Kis of 1217, 1150, 1597, and 1415 nM for the

and LTB4, and reduces the expression of cloned human EP1, EP2, EP3-III, and DP

, with anti-arthritic activity. receptor respectively. AH 6809 has a Ki of 350 nM

for mouse EP2 receptor.

Purity: 99.90% Purity: 99.47% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AM211 AMG-009 (AM211 free acid) Cat. No.: HY-13213 Cat. No.: HY-19499

AM211 is a potent, selective and orally AMG-009 is a potent antagonist of prostaglandin

bioavailable (PGD2) receptor type D2, with IC50 of 3 nM and 12 nM for CRTH2 and DP

2 (DP2) antagonist, with IC50s of 4.9 nM, 7.8 nM, receptors, respectively. 4.9 nM, 10.4 nM for human, mouse, guinea pig, and rat DP2, respectively.

Purity: 99.94% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 1 mg, 5 mg

2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

Asapiprant AZ-1355 (S-555739) Cat. No.: HY-16763 Cat. No.: HY-101692

Asapiprant is a potent and selective DP1 AZ-1355 is an effctive lipid-lowering compound, with a Ki of 0.44 nM. which also inhibits aggregation in vivo

and elevates the prostaglandin I2/

A2 ratio in vitro.

Purity: 99.58% Purity: >98% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg Size: 1 mg, 5 mg

AZ12672857 AZD1981 Cat. No.: HY-136895 Cat. No.: HY-15950

AZ12672857 is an orally active inhibitor of EphB4 AZD1981 is a potent and selective CRTh2

(IC50=1.3 nM) and Src kinases. AZ12672857 shows antagonist; displaces radio-labelled PGD2 from good inhibition of proliferation of c-Src human recombinant DP2 with high potency (pIC50 = transfected 3T3 cells (IC50=2 nM) as well as 8.4). autophosphorylation of EphB4 in transfected CHO-K1 cells (IC50=9 nM). Purity: 98.44% Purity: 99.82% Clinical Data: No Development Reported Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAY 73-1449 BAY-1316957 Cat. No.: HY-118941 Cat. No.: HY-111539

BAY 73-1449 is a selective antagonist of BAY-1316957 is a potent, selective and orally receptor (IP), with high potency (IC50 active prostaglandin E2 receptor subtype 4 (EP4-R) of less than 0.1 nM) in cAMP assays in Human HEL antagonist with an IC50 of 15.3 nM for human cells and rat DRG. BAY 73-1449 can be used in the EP4-R. BAY-1316957 has excellent research of lowering pressure. and properties, and can be used for endometriosis research. Purity: 99.81% Purity: 98.94% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Benorilate sodium (Salipran) Cat. No.: HY-107795 Cat. No.: HY-13569A

Benorylate (Salipran) is the esterification Beraprost sodium, a prostacyclin analog, is a product of and acetylsalicylic acid. stable and orally active of PGI2. Beraprost Benorylate has anti-inflammatory, analgesic and sodium is a potent vasodilator, has the potential antipyretic properties. Benorylate could also for pulmonary arterial hypertension treatment inhibit prostaglandin (PG) synthesis. through expanding renal vessels, improving microcirculation. Purity: 99.80% Purity: 99.88% Clinical Data: Launched Clinical Data: Phase 4 Size: 10 mM × 1 mL, 500 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

BI-671800 Cat. No.: HY-114141 (AGN 192024) Cat. No.: HY-B0191

BI-671800 is a highly specific and potent Bimatoprost is a prostaglandin analog used antagonist of chemoattractant receptor-homologous topically (as eye drops) to control the molecule on Th2 cells (DP2/CRTH2), with IC50 progression of and in the management of values of 4.5 nM and 3.7 nM for PGD2 binding to ocular hypertension. CRTH2 in hCRTH2 and mCRTH2 transfected cells, respectively. Purity: 99.06% Purity: 99.59% Clinical Data: Phase 2 Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

www.MedChemExpress.com 3

Bunaprolast Butaprost (U66858) Cat. No.: HY-U00170 Cat. No.: HY-100448A

Bunaprolast (U66858) is a potent inhibitor of Butaprost is a selective receptor

LTB4 production in human whole blood. (EP2) agonist with an EC50 of 33 nM and a Ki of Bunaprolast (U66858) also exhibits significant 2.4 μM for murine EP2 receptor. Butaprost is

inhibition of lipoxygenase and TXB2 release. less activity against murine EP1, EP3 and EP4 receptors. Butaprost attenuates fibrosis by hampering TGF-β/Smad2 signalling. Purity: >98% Purity: ≥99.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 5 mg (12.24 mM * 1 mL in Methyl acetate),

BW 245C Carbacyclin Cat. No.: HY-101987 (Carbaprostacyclin; Carba-PGI2) Cat. No.: HY-112322

BW 245C is a prostanoid DP-receptor (DP1) agonist, Carbacyclin is a PGI2 analogue, acts as a used to treat stroke. prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.

Purity: 99.14% Purity: ≥99.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg Size: 1 mg

Carboprost tromethamine CAY10471 Cat. No.: HY-A0195 (TM30089) Cat. No.: HY-13706A

Carboprost tromethamine is the synthetic 15-methyl CAY10471 (TM30089) is a potent, selective, and

analogue of prostaglandin F2α. Carboprost orally active prostaglandin D2 receptor tromethamine can effectively promote law CRTH2 antagonist. CAY10471 attenuates the contraction of the uterus and significantly reduce progression of tubulointerstitial fibrosis and the amount of bleeding during and after delivery. chronic contact hypersensitivity (CHS) in animal model. Purity: 98.28% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 1 mg, 5 mg

CAY10471 Racemate CAY10595 (TM30089 Racemate) Cat. No.: HY-13706 Cat. No.: HY-118180

CAY10471 Racemate (TM30089 Racemate) is a potent CAY10595 is a potent CRTH2/DP2 receptor and highly selective prostaglandin D2 receptor antagonist that binds to the human receptor with a

CRTH2 antagonist, with a Ki of 0.6 nM for hCRTH2, Ki of 10 nM. selective over human receptor TP

(Ki, >10000 nM) or PGD2 receptor DP (Ki, 1200 nM). Purity: 99.35% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg Size: 1 mg, 5 mg

Cefminox sodium CGS 15435 (MT-141) Cat. No.: HY-128932 Cat. No.: HY-100283

Cefminox sodium (MT-141) is a semisynthetic CGS 15435, a potent thromboxane (TxA2)

cephamycin, which exhibits a broad spectrum of synthetase inhibitor with an IC50 of 1 nM, has a antibacterial activity. selectivity for Tx synthetase 100000-fold greater

than that for , PGI2 synthetase and lipoxygenase .

Purity: 99.83% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 25 mg Size: 1 mg, 5 mg

4 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

CI-949 CJ-42794 Cat. No.: HY-U00364 (CJ-042794) Cat. No.: HY-10797

CI-949 is an allergic mediator release inhibitor, CJ-42794 is a selective prostaglandin E receptor which inhibits histamine, C4/D4 subtype 4 (EP4) antagonist, inhibits [3H]-PGE2

(LTC4/LTD4), and thromboxane B2 (TXB2) binding to the human EP4 receptor with a mean pKi release with IC50s of 11.4 μM, 0.5 μM and 0.1 μM, of 8.5, a binding affinity that was at least respectively. 200-fold more selective for the human EP4 receptor than other human EP receptor subtypes (EP1,… Purity: >98% Purity: 98.78% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Cloprostenol sodium salt CRTh2 antagonist 1 (ICI 80996 sodium salt) Cat. No.: HY-108415 Cat. No.: HY-112265

Cloprostenol sodium salt (ICI 80996 sodium salt) CRTh2 antagonist 1 is a CRTh2 antagonist with an is a potent synthetic , acts IC50 of 89 nM. as a luteolytic agent, and is a PGF2α receptor agonist.

Purity: 99.81% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 1 mg, 5 mg

CRTh2 antagonist 3 CRTH2-IN-1 Cat. No.: HY-135773 ( analog) Cat. No.: HY-U00423

CRTh2 antagonist 3 is a potent chemoattractant CRTH2-IN-1 (Ramatroban analog) is a selective receptor-homologous molecule expressed on Th2 prostaglandin D2 receptor DP2 (CRTH2) antagonist cells (CRTh2) antagonist. CRTh2 antagonist 3 with an IC50 of 6 nM in a human DP2 binding assay. enhances the activity of PDK1 toward a short peptide substrate, with an EC50 of 2 μM and a

Kd of 8.4 μM. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Daltroban Darbufelone (BM-13505; SKF 96148) Cat. No.: HY-121018 (CI-1004) Cat. No.: HY-101438

Daltroban (BM-13505) is a selective and specific Darbufelone is a dual inhibitor of cellular thromboxane A2 (TXA2) receptor antagonist. PGF2α and LTB4 production. Darbufelone

Daltroban increase intracellular calcium in potently inhibits PGHS-2 (IC50= 0.19 μM) but is vascular smooth muscle cells. Daltroban shows much less potent with PGHS-1 (IC50=20 μM). protective effect in reperfusion injury.

Purity: 95.62% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg Size: 1 mg

Darbufelone mesylate (CI-1004 mesylate) Cat. No.: HY-101438A Cat. No.: HY-106067A

Darbufelone mesylate (CI-1004 mesylate) is a dual Dazoxiben is a potent and orally active inhibitor of cellular PGF2α and LTB4 thromboxane (TX) synthase inhibitor. production. Darbufelone potently inhibits PGHS-2

(IC50 = 0.19 μM) but is much less potent with

PGHS-1 (IC50= 20 μM).

Purity: >98% Purity: 99.87% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

www.MedChemExpress.com 5

DG-041 Dinoprost Cat. No.: HY-10835 (Prostaglandin F2α; PGF2α) Cat. No.: HY-12956

DG-041 is a potent, high affinity and selective Dinoprost (Prostaglandin F2α) is an orally active,

EP3 receptor antagonist with IC50s of 4.6 nM potent prostaglandin F (PGF) receptor (FP and 8.1 nM in the binding and FLIPR assay, receptor) agonist. Dinoprost is a luteolytic respectively. DG-041 inhibits PGE2 facilitation hormone produced locally in the endometrial of platelet aggregation. DG-041 crosses the luminal epithelium and corpus luteum (CL). blood-brain barrier. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: Launched Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Dinoprost tromethamine salt (Prostaglandin F2α tromethamine E7046 salt; PGF2α THAM; Prostaglandin F2α THAM) Cat. No.: HY-12956A Cat. No.: HY-103088

Dinoprost tromethamine salt (Prostaglandin F2α E7046 is an orally bioavailable and specific EP4

tromethamine salt) is an orally active, potent antagonist, with IC50 of 13.5 nM and Ki of 23.14 prostaglandin F (PGF) receptor (FP receptor) nM. E7046 exhibits anti-tumor activities. agonist.

Purity: ≥98.0% Purity: 99.60% Clinical Data: Launched Clinical Data: Phase 1 Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

EP1-antagonist-1 EP4 receptor antagonist 1 Cat. No.: HY-101695 Cat. No.: HY-133123

EP1-antagonist-1 is a EP1 antagonist with a pKi EP4 receptor antagonist 1 is a highly potent and

of 7.54 and an pIC50 of 8.5. selective competitive prostanoid EP4 receptor antagonist for cancer immunotherapy. EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor

with IC50s of 6.1 nM and 16.2 nM, respectively.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

EP4 receptor antagonist 2 EP4 receptor antagonist 3 Cat. No.: HY-136645 Cat. No.: HY-138761

EP4 receptor antagonist 2 (compound 2-13) is a EP4 receptor antagonist 3 is a potent EP4

potent EP4 receptor antagonist with an IC50 of receptor antagonist, example 3,extracted from 7.8 nM. EP4 receptor antagonist 2 shows antitumor patent WO2010019796 A1. activity.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Epibetulinic acid Etersalate Cat. No.: HY-N0223 (Eterylate; Etherylate) Cat. No.: HY-101606

Epibetulinic acid, isolated from the root bark of Etersalate inhibits platelet function and Maytenus cuzcoina and the leaves of Maytenus decreases thromboxane A2 (TXA2) levels. chiapensis, exhibits potent inhibitory effects on NO and prostaglandin E2 (PGE2) production in mouse macrophages (RAW 264.7) stimulated with

bacterial endotoxin with IC50s of 0.7 and 0.6… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

6 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

Ethamsylate Evatanepag Cat. No.: HY-B1074 (CP-533536 free acid) Cat. No.: HY-14839

Ethamsylate is a haemostatic drug, also inhibits Evatanepag (CP-533536) is an EP2 receptor biosynthesis and action of those prostaglandins. selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM. IC50 value: 0.3 nM (EC50) Target PGE2 in vitro: CP-533536 is a potent and selective EP2agonist.

Purity: ≥99.0% Purity: 99.80% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Fevipiprant Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; (QAW039; NVP-QAW039) Cat. No.: HY-16768 Chikusetsusaponin V) Cat. No.: HY-N0607

Fevipiprant (QAW039; NVP-QAW039) is a selective, Ginsenoside Ro (Polysciasaponin P3; potent, reversible competitive CRTh2 antagonist Chikusetsusaponin 5; Chikusetsusaponin V) exhibits with an in vitro KD value of a Ca2+-antagonistic antiplatelet effect with an

1.1nM at the CRTh2 receptor and an IC50 value of IC50 of 155 μM. Ginsenoside Ro reduces the

0.44 nM for inhibition of PGD2-induced production of TXA2 more than it reduces the shape change in human whole blood. activities of COX-1 and TXAS. Purity: 99.63% Purity: 99.21% Clinical Data: Phase 3 Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg Size: 10 mM × 1 mL, 5 mg, 10 mg

Grapiprant GSK-269984A (CJ-023423; RQ-00000007; AAT-007) Cat. No.: HY-16781 Cat. No.: HY-14467

Grapiprant (CJ-023423) is a selective EP4 GSK-269984A is a Prostaglandin E2 Receptor 1 (EP1) receptor antagonist whose physiological is antagonist with a pIC50 of 7.9. prostaglandin E2 (PGE2). Grapiprant displaces 3 [ H]-PGE2 (1 nM) binding to dog recombinant EP4 receptor with IC50 value of 35 nM and Ki value of 24 nM. Purity: 99.45% Purity: >98% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg Size: 1 mg, 5 mg

GSK726701A GW627368 Cat. No.: HY-112152 Cat. No.: HY-16963

GSK726701A is a novel prostaglandin E2 receptor 4 GW627368 (GW627368X) is a novel, potent and

(EP4) partial agonist with a pEC50 of 7.4. selective competitive antagonist of prostanoid EP4 receptor with additional human TP receptor

affinity, with pKi values of 7.0 and 6.8 for human prostanoid EP4 and TP receptors respectively.

Purity: 98.72% Purity: 99.97% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Iloprost KAG-308 (Ciloprost; ZK 36374) Cat. No.: HY-A0096 Cat. No.: HY-128686

Iloprost (ZK 36374) is a synthetic analogue of KAG-308 is a potent selective and orally active prostacyclin PGI2. agonist of EP4 receptor (a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF-α production.

Purity: 99.06% Purity: 98.61% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 5 mg, 10 mg, 50 mg, 100 mg

www.MedChemExpress.com 7

KF 13218 KMN-80 Cat. No.: HY-U00231 Cat. No.: HY-118743

KF 13218 is a potent, selective and long lasting KMN-80, a derivative of PGE1 (HY-B0131), is a

thromboxane B2 (TXB2) synthase inhibitor with selective and potent agonist of EP4 receptor

an IC50 value of 5.3±1.3 nM. with an IC50 and a Ki of 3 nM and 2.35 nM,

respectively. KMN-80 is against EP3 receptor with

an IC50 of 1.4 μM and >10 μM for all other prostanoid receptors. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg

KP496 KW-8232 Cat. No.: HY-U00253 Cat. No.: HY-100304A

KP496 is a selective, dual antagonist for KW-8232, an orally active anti-osteoporotic agent, Leukotriene D4 receptor and Thromboxane A2 and can reduces the biosynthesis of PGE2. receptor.

Purity: 95.81% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg Size: 1 mg, 5 mg

KW-8232 free base L 888607 Cat. No.: HY-100304 Cat. No.: HY-111271

KW-8232 free base, an orally active L 888607 is a potent, and selective CRTH2 (also

anti-osteoporotic agent, and can reduces the known as DP2) agonist with a Ki of 0.8 nM. biosynthesis of PGE2.

Purity: ≥90.0% Purity: 99.88% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L 888607 Racemate L-161982 Cat. No.: HY-111271A Cat. No.: HY-108559

L 888607 Racemate is a selective prostaglandin D2 L-161982 is a selective EP4 receptor antagonist.

receptor subtype 1 (DP1) antagonist, with Kis of L-161982 completely blocks PGE2-induced ERK 132 nM and 17 nM for DP1 and thromboxane A2 phosphorylation and cell proliferation of HCA-7 receptor (TP), respectively. cells. L-161982 alleviates collagen-induced arthritis in mice.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

L-798106 L-902688 (CM9; GW671021) Cat. No.: HY-15274 Cat. No.: HY-119163

L-798106 is potent and highly selective prostanoid L-902688 is a potent, selective and orally active

EP3 receptor antagonist (Ki=0.3 nM), it also has EP4 receptor agonist with a Ki of 0.38 nM and an

micromolar activities at the EP4, EP1 and EC50 of 0.6 nM. L-902688 shows >4,000-fold

EP2 receptors with Ki values of 916 nM, >5000 selective for EP4 over other EP and prostanoid nM and >5000 nM at EP4, EP1 and EP2, receptors. respectively. Purity: ≥98.0% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg Size: 1 mg, 5 mg

8 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

Laflunimus (HR325) Cat. No.: HY-101813 (MK-0524) Cat. No.: HY-50175

Laflunimus (HR325) is an immunosuppressive agent Laropiprant is a potent, selective DP receptor and an analogue of the Leflunomide-active antagonist with Ki values of 0.57 nM and 2.95 nM metabolite A77 1726. Laflunimus is an orally for DP receptor and TP Receptor, respectively. active inhibitor of dihydroorotate dehydrogenase (DHODH).

Purity: 99.26% Purity: 99.73% Clinical Data: No Development Reported Clinical Data: Phase 4 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Latanoprost acid (PHXA41) Cat. No.: HY-B0577 Cat. No.: HY-113756A

Latanoprost (PHXA41) is a prostaglandin F2α Latanoprost acid, an analog of prostaglandin (PG) analogue and an agonist for the FP prostanoid F2α, is an selective prostanoid receptor (FP) receptor, and lowers intraocular-pressure (IOP). agonist that specifically activates the FP-PG receptor.

Purity: 99.83% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 1 mg, 5 mg

Latanoprost lactone diol LCB-2853 Cat. No.: HY-125946 Cat. No.: HY-101700

Latanoprost lactone diol is an intermediate in the LCB-2853 is an antagonist of thromboxane A2 synthesis of Latanoprost. Latanoprost is a (TXA2) receptor, with antiplatelet and prostaglandin F2α analogue and an agonist for the activities. FP prostanoid receptor, and lowers intraocular-pressure (IOP).

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Licarin A MF498 ((+)-Licarin A) Cat. No.: HY-N2252 Cat. No.: HY-10794

Licarin A ((+)-Licarin A), a neolignan isolated MF498 is a novel and selective E prostanoid from various plants, significantly and receptor 4 (EP4 receptor) antagonist, displayed dose-dependently reduces TNF-α production strong binding affinity for the EP4 receptor with

(IC50=12.6 μM) in dinitrophenyl-human serum albumin Ki of 0.7 nM. (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects. Purity: >98% Purity: 98.90% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Misoprostol acid acid D5 Cat. No.: HY-118189 Cat. No.: HY-118189S

Misoprostol acid is an active metabolite of Misoprostol acid D5 is deuterium labeled Misoprostol. Misoprostol is a synthetic analogue Misoprostol acid. Misoprostol acid is an active of (PGE1), extensively absorbed, metabolite of Misoprostol. and undergoes rapid de-esterification to Misoprostol acid in the after oral administration. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg Size: 1 mg

www.MedChemExpress.com 9

MK-2894 MK-2894 sodium salt Cat. No.: HY-10413 Cat. No.: HY-10414

MK-2894 is a potent, selective, orally active and MK-2894 sodium salt is a potent, selective, orally

high affinity (Ki=0.56 nM) full antagonist against active and high affinity (Ki=0.56 nM) full

E prostanoid receptor 4 (EP4 receptor) (IC50=2.5 antagonist against E prostanoid receptor 4 (EP4

nM). MK-2894 possesses potent anti-inflammatory receptor) (IC50=2.5 nM). activity in animal models of pain/inflammation and can be used for the research of arthritis. Purity: 98.10% Purity: 98.09% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MK-447 MK-7246 Cat. No.: HY-100297 Cat. No.: HY-15853

MK-447 is a free radical scavenger, also a MK-7246 is a potent and selective CRTH2

nonsteroidal antiinflammatory agent, and enhances antagonist with a Ki of 2.5±0.5 nM.

the formation of the endoperoxide, PGH2, and other prostaglandins.

Purity: >98% Purity: 98.16% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK-7246 S enantiomer MK-8318 Cat. No.: HY-15853A Cat. No.: HY-112604

MK-7246 S enantiomer is the less active enantiomer MK-8318 is a potent and selective CRTh2 receptor

of MK-7246. MK-7246 is a potent and selective antagonist with a Ki of 5.0 nM. CRTH2 antagonist.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

MRE-269 (ACT-333679) Cat. No.: HY-79593 (FPL 59002) Cat. No.: HY-13448

MRE-269 is an active metabolite of , and Nedocromil suppresses the action or formation of acts as a selective IP receptor agonist. multiple mediators, including histamine,

leukotriene C4 (LTC4), and prostaglandin D2

(PGD2).

Purity: 99.46% Purity: 98.86% Clinical Data: No Development Reported Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg

Nedocromil sodium NTP42 (FPL 59002KP; Nedocromil disodium salt) Cat. No.: HY-16344 Cat. No.: HY-129851

Nedocromil sodium suppresses the action or NTP42 is a thromboxane A2 (TXA2) receptor

formation of multiple mediators, including antagonist with an IC50 of 3.278 nM for

histamine, leukotriene C4 (LTC4), and antagonizing T prostanoid receptor (TP)- mediated 2+ prostaglandin D2 (PGD2). [Ca ] mobilization following stimulation of cells with the alternative TP agonist U46609.

Purity: >98% Purity: 98.43% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

10 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

OBE022 Omidenepag Cat. No.: HY-112284 Cat. No.: HY-17642

OBE022 is an oral and selective prostaglandin F2α Omidenepag,a pharmacologically active form of

(PGF2α) receptor antagonist, with Kis of 1 nM, Omidenepag Isopropyl, is a selective, 26 nM for human and rat FP receptors, non-prostanoid EP2 receptor agonist, with an respectively. EC50 of 1.1 nM. Omidenepag shows binding

affinities (IC50) 10 nM for h-EP2.

Purity: >98% Purity: 99.78% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Omidenepag isopropyl ONO-AE3-208 Cat. No.: HY-111406 (AE 3-208) Cat. No.: HY-50901

Omidenepag isopropyl is a selective EP2 receptor ONO-AE3-208 is an EP4 antagonist, and suppresses agonist. Omidenepag isopropyl is converted to the cell invasion, migration, and metastasis of active product Omidenepag during corneal prostate cancer. penetration, and Omidenepag is a highly selective EP2 receptor agonist.

Purity: 98.07% Purity: 98.65% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ozagrel hydrochloride (OKY-046) Cat. No.: HY-B0428 (OKY-046 hydrochloride) Cat. No.: HY-B0428B

Ozagrel (OKY-046)is an anti-asthmatic agent and a Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which Ozagrel hydrochloride is an antiplatelet agent, selectively inhibits human platelet aggregation which selectively inhibits human platelet with an IC50 of 53.12 μM. aggregationwith an IC50 of 53.12 μM.

Purity: 99.96% Purity: ≥98.0% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ozagrel sodium p-Hydroxycinnamic acid (OKY-046 sodium) Cat. No.: HY-B0428A Cat. No.: HY-N2391

Ozagrel sodium (OKY-046 sodium) is a p-Hydroxycinnamic acid, a common dietary phenol, thromboxane A2 (TXA2) synthase inhibitor. could inhibit platelet activity, with IC50s of 371

Ozagrel sodium is an antiplatelet agent, which μM, 126 μM for thromboxane B2 production and selectively inhibits human platelet aggregation lipopolysaccharide-induced prostaglandin E2 with an IC50 of 53.12 μM. generation, respectively.

Purity: 99.91% Purity: 99.85% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Pectolinarin PF-04418948 Cat. No.: HY-N0314 Cat. No.: HY-18966

Pectolinarin, isolated from Cirsium PF-04418948 is an orally active, potent and chanroenicum, possesses anti-inflammatory selective prostaglandin EP2 receptor antagonist activity. Pectolinarin inhibits secretion of IL-6 with an IC50 of 16 nM. and IL-8, as well as the production of PGE2 and NO.

Purity: 99.89% Purity: 99.22% Clinical Data: No Development Reported Clinical Data: Phase 1 Size: 5 mg, 10 mg, 20 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

www.MedChemExpress.com 11

Pizuglanstat Prostaglandin D2 Cat. No.: HY-109134 (PGD2) Cat. No.: HY-101988

Pizuglanstat (compound 3) is a prostaglandin D Prostaglandin D2 (PGD2) is one of the major PGs

synthase inhibitor with an IC50 of 76 nM for actively produced in the brain of various mammals. human hematopoietic prostaglandin D synthases Prostaglandin D2 is one of the most potent (H-PGDS). Pizuglanstat can be used for endogenous sleep promoting substances. PGD2 plays myodegenerative disease research, such as muscular a protective role by suppressing inflammation. dystrophy. Purity: 99.40% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 5 mg

Prostaglandin E1 Prostaglandin E2 (PGE1) Cat. No.: HY-B0131 (Dinoprostone) Cat. No.: HY-101952

Prostaglandin E1 (PGE1) is a potent vasodilator Prostaglandin E2 is a hormone-like substance that and activates the prostaglandin E1 (EP) receptor. participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation. Purity: 98.03% Purity: 98.36% Clinical Data: Launched Clinical Data: Launched Size: 5 mg, 10 mg, 50 mg Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Quinotolast sodium Ralinepag (FR71021) Cat. No.: HY-U00027 (APD811) Cat. No.: HY-16751

Quinotolast sodium in the concentration range of Ralinepag is a potent, orally bioavailable and

1-100 μg/mL inhibits histamine, LTC4 and non-prostanoid prostacyclin (IP) receptor agonist,

PGD2 release in a concentration-dependent with EC50s of 8.5 nM, 530 nM and 850 nM for manner. human and rat IP receptor and human DP1 receptor, respectively.

Purity: >98% Purity: 99.70% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ramatroban (BAY u3405) Cat. No.: HY-B0745 (OPC12759; Proamipide) Cat. No.: HY-B0360

Ramatroban is a selective thromboxane A2 Rebamipide (OPC12759) is a mucoprotective agent.

(TxA2, IC50=14 nM) antagonist, which also Rebamipide induces COX-2 expression, increases

antagonizes CRTH2 (IC50=113 nM) by inhibiting PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner. PGD2 binding.

Purity: 99.10% Purity: 99.88% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Rebamipide D4 RO1138452 (OPC12759 D4; Proamipide D4) Cat. No.: HY-B0360S (CAY10441) Cat. No.: HY-108912

Rebamipide D4 (OPC12759 D4) is deuterium labeled RO1138452 is a potent and selective IP Rebamipide. Rebamipide is a mucoprotective agent. (prostacyclin) receptor antagonist. RO1138452 Rebamipide induces COX-2 expression, increases displays high affinity for IP receptors. In human

PGE2 levels, and enhances gastric mucosal defense , pKi is 9.3±0.1; in a recombinant IP

in a COX-2-dependent manner. receptor system, pKi is 8.7±0.06.

Purity: >98% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

12 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

RS-601 Saikogenin D Cat. No.: HY-U00072 Cat. No.: HY-N4237

RS-601 is a novel leukotriene D4 (LTD4)/thromboxane Saikogenin D is isolated from Bupleurum A2 (TxA2) dual receptor antagonist, with chinense, has anti-inflammatory effects. antiasthmatic activities.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Selexipag (NS-304; ACT-293987) Cat. No.: HY-14870 (AA 2414) Cat. No.: HY-B0774

Selexipag (NS-304) is an orally available and Seratrodast(AA 2414) is an anti-asthmatic agent potent agonist for the Prostacyclin (PGI2) and a potent and selective thromboxane A2 receptor receptor (IP receptor). (TP) antagonist.

Purity: 99.89% Purity: 99.68% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Setipiprant (ACT-129968; KYTH-105) Cat. No.: HY-16635 (SHB 286; CP-34089; ZK-57671) Cat. No.: HY-19360

Setipiprant is an orally available, selective Sulprostone (SHB 286) is a potent and selective CRTH2 antagonist. CRTH2 is a G protein-coupled EP3 receptor agonist. Sulprostone (SHB 286) is a receptor for PGD2. prostaglandin E2 (PGE2) analogue and has antiulcer and nonsteroidal abortifacient effects.

Purity: 98.17% Purity: ≥99.0% Clinical Data: Phase 3 Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg Size: 1 mg, 5 mg

Taprenepag Taprenepag isopropyl (CP-544326) Cat. No.: HY-14899 (PF-04217329) Cat. No.: HY-19998

Taprenepag (CP-544326) is a potent and selective Taprenepag isopropyl is a highly selective EP2 prostaglandin EP(2) agonist with IC50s of 10 and receptor agonist. 15 nM for human and rat EP2, respectively. Taprenepag shows selectivity for EP2 over other EP receptors (IC50s>3200 nM for EP1, EP3, and EP4) and a panel of 37 G protein-coupled receptors. Purity: 99.26% Purity: 98.77% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Terbogrel (BIBV 308SE) Cat. No.: HY-19189 (S-18886) Cat. No.: HY-16991

Terbogrel is an orally available thromboxane A2 Terutroban is a thromboxane-prostaglandin receptor antagonist and a thromboxane A2 receptor antagonist. synthase inhibitor, with both IC50s of about 10 nM.

Purity: >98% Purity: 99.97% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg

www.MedChemExpress.com 13

TG4-155 TG6-10-1 Cat. No.: HY-18971 Cat. No.: HY-16978

TG4-155 is a potent, brain-permeant and selective TG6-10-1 is an EP2 antagonist, shows

EP2 receptor antagonist with a Ki of 9.9 nM. low-nanomolar antagonist activity against only TG4-155 shows low nanomolar antagonist activity EP2, >300-fold selectivity over human EP3, EP4, against only EP2 and DP1. and IP receptors, 100-fold selectivity over EP1 receptors.

Purity: 99.12% Purity: 99.28% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tiaprost Timapiprant (Iliren) Cat. No.: HY-111478 (OC000459) Cat. No.: HY-15342

Tiaprost is a prostaglandin F2α (PGF2α) Timapiprant (OC000459) is a potent, selective, and

analogue. orally active D prostanoid receptor 2 (DP2, also known as CRTH2) antagonist.

Purity: ≥98.0% Purity: 98.52% Clinical Data: No Development Reported Clinical Data: Phase 2 Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Timapiprant sodium Tranilast (OC000459 sodium) Cat. No.: HY-15342A (MK-341; SB 252218) Cat. No.: HY-B0195

Timapiprant sodium (OC000459 sodium) is a potent, Tranilast (MK-341) acts as an anti-atopic agent. selective, and orally active D prostanoid receptor Tranilast suppresses production of prostaglandin

2 (DP2, also known as CRTH2) antagonist. D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects.

Purity: 99.91% Purity: 99.46% Clinical Data: Phase 2 Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 10 mM × 1 mL, 10 mg, 50 mg

Tranilast sodium (MK-341 sodium; SB 252218 sodium) Cat. No.: HY-B0195A (Fluprostenol isopropyl ester; AL6221; Flu-Ipr) Cat. No.: HY-B0584

Tranilast sodium (MK-341 sodium) acts as an Travoprost (Fluprostenol isopropyl ester), an anti-atopic agent. Tranilast suppresses production isopropyl ester prodrug, is a high affinity,

of prostaglandin D2 (PGD2, IC50= 0.1 mM). selective FP prostaglandin full receptor agonist. Tranilast sodium exhibits anti-inflammatory and Travoprost has the ocular hypotensive efficacy and immunomodulatory effects. has the potential for glaucoma and ocular hypertension. Purity: >98% Purity: 99.99% Clinical Data: Launched Clinical Data: Launched Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Treprostinil sodium (LRX-15) Cat. No.: HY-100441 (UT-15) Cat. No.: HY-16504

Treprostinil (LRX-15) is a potent DP1 and EP2 Treprostinil sodium is a potent DP1 and EP2

agonist with EC50 values of 0.6±0.1 and 6.2±1.2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively. nM, respectively.

Purity: 99.98% Purity: ≥98.0% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

14 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

U-46619 Vidupiprant (9,11-Methanoepoxy PGH2) Cat. No.: HY-108566 (AMG 853) Cat. No.: HY-14973

U-46619 (9,11-Methanoepoxy PGH2) is a stable Vidupiprant (AMG 853) is a phenylacetic acid analogue of thromboxane A2 (TXA2) and acts as a derivative. Vidupiprant is a potent and orally potent TXA2 agonist. active CRTH2 (DP2) and prostanoid D receptor (DP

or DP1) dual antagonist with IC50s of 3 nM and 4 nM in buffer, and 8 nM and 35 nM in human plasma, respectively. Purity: ≥99.0% Purity: 98.08% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg (28.5 mM * 500 μL in Methyl acetate) Size: 10 mg, 50 mg, 100 mg

YM158 free base (YM-57158) Cat. No.: HY-U00355

YM158 free base is a potent and selective LTD4 and TXA2 receptor antagonist with pA2 values of about 8.87 and 8.81, respectively.

Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg

www.MedChemExpress.com 15